Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021
Haematologica
.
2021 Jul 1;106(7):1787-1793.
doi: 10.3324/haematol.2020.267252.
Authors
Tariq I Mughal
1
,
Bethan Psaila
2
,
Daniel J DeAngelo
3
,
Giuseppe Saglio
4
,
Richard A Van Etten
5
,
Jerald P Radich
6
Affiliations
1
Tufts University Medical Center, Boston, MA, USA; University of Buckingham Medical School, Buckingham. tariq.mughal@tufts.edu.
2
MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford.
3
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
4
Orbassano University Hospital, Turin.
5
University of California Irvine, Irvine, CA.
6
Frederick Hutchinson Cancer Research Center, Seattle, WA.
PMID:
33657787
PMCID:
PMC8252942
DOI:
10.3324/haematol.2020.267252
No abstract available
MeSH terms
Humans
Molecular Biology
Myeloproliferative Disorders* / genetics
Neoplasms*
Grants and funding
28051/CRUK_/Cancer Research UK/United Kingdom
29034/CRUK_/Cancer Research UK/United Kingdom